Author: openjargon

Most ASX lithium stocks are rising on Thursday amid a 58% increase in the lithium carbonate price in 2026 alone.

The lithium carbonate price is US$27,528 per tonne at the time of writing.

It rose nearly 6% in the last trading session and is up 18% over the past month and 181% year over year.

Lithium carbonate is now at its highest level since 2023 amid renewed and growing long-term demand for lithium batteries.

The lithium spodumene price has also ripped from less than US$600 per tonne in June last year to US$2,752 per tonne today.

Lithium prices endured a two-year downward spiral before turning a corner in mid-2025 as supply and demand rebalanced.

The green energy transition is the key driver of new demand, while the global oil shock has highlighted the draw of electric vehicles (EVs).

On top of that, supply has rebalanced after many young lithium miners shuttered their operations in 2023 and 2024 as prices collapsed.

Analysts at Trading Economics said:

The surge in crude oil and product prices since the start of March supported the outlook for larger economies to favor new energy vehicles, which use batteries that take lithium as a major input.

Demand also remained supported by Chinese investment in power infrastructure, recently consolidated with Beijing stating it would double national EV charging capacity to 180 gigawatts by 2027.

Fresh buying is also featured from data center operators, whose power storage systems require more lithium than those used by EVs, on the historical capital investments by AI companies and hardware producers.

Lithium is leaving other commodities in the dust when it comes to year-to-date (YTD) growth.

The 58% gain for lithium carbonate compares to 3.5% for iron ore, 8.9% for gold, 8% for copper, and 9% for silver.

How are ASX lithium stocks performing today?

Today, the best performing ASX lithium shares for price growth include IGO Ltd (ASX: IGO), up 4.3% to $8.43 per share.

The IGO share price is up 2.6% in the YTD and 103% over 12 months.

Mineral Resources Ltd (ASX: MIN) shares are up 2.1% to $71.42 on Thursday.

The Mineral Resources share price is up 29% in the YTD and up 242% over 12 months.

The Liontown Ltd (ASX: LTR) share price is down 1.2% today at $2.51.

However, Liontown shares have been on a tear this year, up 55% YTD and up 348% over 12 months.

The market’s largest pure-play lithium company, PLS Group Ltd (ASX: PLS), cracked a new record at $6.38 today.

The PLS Group share price is currently $6.34, up 1.6% for the day and up 47.1% in the YTD.

Which ASX lithium stocks are a buy?

On the CommSec trading platform, IGO shares have a consensus moderate buy rating from 16 analysts.

UBS is among the brokers with a buy recommendation.

Late last month, the broker raised its price target from $9.05 to $9.75, implying a 15% upside from here.

Mineral Resources has a consensus moderate buy rating among 15 analysts tracking the ASX lithium stock on CommSec.

Morgans has an accumulate rating and recently raised its 12-month target from $67 to $71.

In a new note, the broker described a “compelling outlook supported by continued deleveraging and commodity prices”.

Liontown shares have a consensus hold rating among 12 analysts rating it on CommSec.

Morgans downgraded Liontown shares from hold to trim but with an improved $2.20 price target this week.

The broker said:

Weak 3Q26 result was driven by lower recoveries, though ramp-up is progressing well and cash flow turned positive.

Outlook is improving with recoveries and spodumene prices lifting.

Move to a TRIM with a A$2.20ps TP on valuation but the outlook remains positive.

PLS Group shares score a consensus moderate hold rating from 18 analysts on CommSec.

The hold rating is unsurprising given the market’s largest ASX lithium stock by market cap is trading at record price levels.

Bell Potter is among the brokers with a hold rating on PLS Group shares.

In a recent note, the broker said:

At current lithium market prices, PLS will generate substantial earnings and cash flow ahead of the restart of the 200ktpa Ngungaju processing plant.

P2000 and Colina development studies are being progressed, providing substantial organic growth optionality in markets with strong underlying EV and BESS-led long term demand fundamentals.

The post ASX lithium stocks to buy amid commodity price rocketing 58% already this year appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Mineral Resources, Fortescue, Champion Iron shares
• 4 top ASX 200 shares including Rio Tinto and Macquarie notching new 52-week plus highs today
• Up more than 100% in a year, is it time to take profits on IGO shares?
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Mineral Resources, Dyno Nobel, Iluka Resources shares

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

4DMedical Ltd (ASX: 4DX) shares are being sold off again on Thursday as investors take another look at one of the ASX’s hottest stocks.

At the time of writing, the 4DMedical share price is down a sizeable 10.39% to $3.405.

That puts the stock down around 40% over the past month. It also leaves the share price more than 50% below its recent high of $7.37, which was reached on 14 April.

While the move is not being driven by any new announcements today, the sell-off appears tied to weaker momentum after a huge recent run.

Here’s what investors are looking at.

A huge rally is now unwinding

This pullback follows a massive run in the share price.

Even after the recent drop, 4DMedical shares are still up around 1,040% since this time last year.

The stock has been helped by a string of updates over the past 12 months. These include regulatory progress, commercial agreements, and stronger interest in the company’s lung imaging technology.

Its CT:VQ platform uses existing CT scans to create detailed maps of lung ventilation and blood flow. 4DMedical has previously highlighted US clearance, UK certification, and a commercial contract with GlaxoSmithKline as key steps.

That run helped send the share price to an all-time high in April.

Since then, investors appear to have been locking in gains as sentiment has cooled.

The stock has recorded several heavy down days, falling 5.47% yesterday and more than 20% over the past week.

The chart looks under pressure

The technical picture has also weakened.

The stock has broken well below its recent highs and is now trading near the bottom end of its recent range. The overall trend since mid-April has been lower, with each bounce struggling to hold.

The relative strength index (RSI) is sitting around 29, which puts the stock close to oversold territory. Meanwhile, the Bollinger Bands show the share price trading near the lower end of its recent range.

The lower band is sitting around $2.75, while the upper band is above $5.

From here, the first support area looks to be around $3.30, near the recent intraday low. If that breaks, the next level to watch could be closer to the lower Bollinger Band near $2.75.

Foolish takeaway

I can see why investors are taking some money off the table after such a big run.

4DMedical has clear commercial progress, but the stock had raced a long way ahead of current earnings.

Personally, I would not be chasing this sell-off today. I would want to see the share price settle first, especially around the $3.30 support area.

The post Why this ASX 200 rocket stock is crashing again today appeared first on The Motley Fool Australia.

More reading

• Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?
• Buy, hold, sell: Minerals 260, 4DMedical, Karoon Energy shares
• Why this ASX healthcare high-flyer just dropped another 9% today
• The ASX’s hottest shares just stumbled — warning sign?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Are you looking for ASX dividend shares to buy? If you are, it could be worth considering the two in this article.

That’s because Morgans has just rated them as buys and is forecasting attractive dividend yields. Here’s what the broker is recommending to clients:

Accent Group Ltd (ASX: AX1)

The first ASX dividend share that could be a buy according to Morgans is footwear retailer Accent Group.

While it has been a tough period for the company, Morgans thinks its shares have been oversold, creating an opportunity for investors.

It has put a buy rating and 75 cents price target on its shares. It said:

AX1 has provided a soft trading update for 2H26, revising guidance lower and disclosed an ASIC insider trading investigation. The trading update for AX1 has materially softened since the update in February, with the escalations in the Middle East resulting in higher fuel prices and lower consumer confidence which in turn has impacted sales and margins. 2H26 EBIT guidance has been lowered to $23-28m (from $30-35m). We have lowered our EBIT by 9%/6% respectively in FY26/27.

Our valuation lowers to $1.00, which we apply a 25% discount to derive a target price of $0.75. This reflects the weakening consumer backdrop, as well as overhang from ASIC investigation. We maintain our BUY recommendation.

With respect to income, the broker is forecasting fully franked dividends per share of 3.8 cents in FY 2026 and then 4.9 cents in FY 2027. Based on its current share price of 55 cents, this equates to 6.9% and 8.9% dividend yields, respectively.

Pinnacle Investment Management Group Ltd (ASX: PNI)

Another ASX dividend share that Morgans is positive on is Pinnacle Investment Management.

Morgans responded positively to this investment management company’s quarterly update and has retained its buy rating with an improved price target of $24.70.

Commenting on the company, the broker said:

PNI has released its 3Q26 update. The key highlight of the update was 3Q26 flows coming in stronger than expected amid a volatile environment, with PNI’s additional 6.8% investment in Metrics acting as a further vote of confidence in the business. We make mild upgrades to PNI’s FY26F/FY27F/FY28F EPS of ~1%-3%, driven by higher net flow forecasts and the earnings contribution from the increased Metrics stake. Our PT edges up to A$24.70 (from A$23.21) and we maintain our BUY call.

As for income, Morgans is forecasting fully franked dividends of 64 cents per share in FY 2026 and then 81 cents per share in FY 2027.

Based on its current share price of $16.41, this equates to dividend yields of 3.9% and 4.9%, respectively.

The post Morgans says these ASX dividend shares are buys appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• CSL and Wesfarmers among scores of ASX shares hitting fresh 52-week lows
• Pinnacle Investment Management increases Metrics Credit stake in $100.5 million deal
• Here are the top 10 ASX 200 shares today
• Why Accent shares just crashed to a 13-year low

Motley Fool contributor James Mickleboro has positions in Accent Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has recommended Accent Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Three discoveries on the trot have the team at Canaccord Genuity excited about Gorilla Gold Mines Ltd (ASX: GG8), which they say has the potential to more than double in value.

Let’s have a look at the most recent discovery.

Excellent drilling results

Gorilla, in a statement released to the ASX earlier this week, said it had struck a significant intercept at the Sovereign deposit at its Comet Vale gold project in Western Australia.

The drilling intersected 9.3m at 20.6 grams per tonne of gold, in what was “a brand new discovery” at the deposit, the company said.

Gorilla added:

The mineralisation occurs 50m into the footwall of the main lode at Sovereign, a largely untested position, and is visually very different from the mineralisation typically seen at Sovereign. The scale potential of this new high-grade lode is currently under evaluation, noting that individual lodes at Comet Vale are typically continuous over many hundreds of metres both along strike and down-dip.

The company also reported a number of other high-grade results from further drilling at Sovereign.

Gorilla Chief Executive Officer Charles Hughes said regarding the recent discovery:

This is a standout result, one of the best intercepts we’ve delivered at Sovereign, and it’s exciting to get this in a discovery hole in a new high-grade lode position that has seen very little effective drill testing. “Importantly, this mineralisation is geologically distinct from the main Sovereign lodes – in fact, if it wasn’t for the presence of some very coarse gold, it could have been missed! There is no quartz veining and only a tiny amount of sulphides associated with the new lode, which means it would be very easy to overlook. We are now fast-tracking work to define the extent of this lode, including sampling of historical holes that intersected this position and drilling targeted step-outs to specifically target its lateral extents.

Mr Hughes said the company also continued to deliver “excellent” results from its growth drilling at Sovereign.

He added:

With established infrastructure, advanced permitting and proximity to multiple processing options, we are well positioned to rapidly unlock value from these exciting new discoveries at Comet Vale.

Shares looking cheap

The Canaccord team noted that Gorilla’s overall North Kalgoorlie Hub hosted about 1.2 million ounces of gold and remains underexplored.

Canaccord has a speculative buy rating on Gorilla Gold Mines shares and a price target of $1 compared with the current share price of 41 cents.

Gorilla Gold Mines is valued at $278.2 million.

The post This ASX gold explorer could more than double on the back of three recent discoveries: broker appeared first on The Motley Fool Australia.

More reading

• Guess which ASX All Ords gold stock is rocketing 9% today on ‘high-grade’ results

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today as the company reported Q1 2026 DAYBUE® net sales grew 20% year-on-year, reaching US$101 million. Neuren also saw its Q1 royalty income rise 23% to US$10.4 million, as DAYBUE continued strong momentum.

What did Neuren Pharmaceuticals report?

• Q1 2026 DAYBUE® net sales: US$101 million (up 20% from Q1 2025)
• Q1 2026 royalty income: US$10.4 million (up 23% from Q1 2025)
• Over 250 DAYBUE STIX prescriptions written in Q1 with >80% caregiver satisfaction
• Acadia reaffirmed 2026 DAYBUE net sales guidance: US$460–490 million
• Expected full year 2026 royalty income: US$50–54 million (A$70–77 million)

What else do investors need to know?

Neuren’s partner Acadia recently launched DAYBUE STIX, a new powder version of trofinetide, in the US. Early uptake has been positive, with a high rate of caregiver satisfaction and strong support from healthcare professionals.

A Delphi expert panel now recommends DAYBUE as part of the standard of care for eligible patients with Rett syndrome. Outside the US, clinical trial enrolment in Japan has accelerated, with top-line results now expected between September and November 2026, bringing the timeline forward.

What did Neuren Pharmaceuticals management say?

Neuren CEO Jon Pilcher said:

This was a strong start to the year for DAYBUE. I am very encouraged by the initial uptake and enthusiasm for DAYBUE STIX following the limited launch in Centers of Excellence (COEs) and I look forward to seeing the impact of the recent broader US launch. I see significant potential upside remaining in the US, with penetration rates currently ~60% in the COEs and ~28% in the broader community.

What’s next for Neuren Pharmaceuticals?

Looking ahead, Neuren expects steady growth as DAYBUE roll-out continues in the US, with broader availability for the new STIX powder formulation. The company’s royalty income is forecast to rise in line with guidance, underpinned by increasing adoption and favourable expert recommendations.

Internationally, results from the ongoing trofinetide trial in Japan are now due earlier than previously planned. In Europe, a regulatory review for trofinetide is set to conclude by June 2026. Neuren’s pipeline also includes NNZ-2591, now in Phase 3 trials for Phelan-McDermid syndrome.

Neuren Pharmaceuticals share price snapshot

Over the past 12 months, Neuren Pharmaceuticals shares have risen 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar appeared first on The Motley Fool Australia.

More reading

• Cleanaway Waste Management hit with landfill levy ruling
• Why Amcor, Credit Corp, Neuren, and Zip shares are charging higher today
• Superloop lifts revenue and customer base
• BWP Group announces successful entitlement offer
• Tabcorp faces AUSTRAC compliance probe

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Atlantic Lithium Ltd (ASX: A11) have jumped more than 10% after the company said it had agreed to a takeover by a Chinese company.

Share price upside on the table

Atlantic Lithium said in a statement to the ASX that it had entered into a binding scheme of arrangement with Zhejiang Huayou Cobalt Co. to be taken over for a price of 35.4 cents per share.

The company’s shares immediately jumped on the news to be changing hands for 31.5 cents, up 12.5%.

The takeover will be executed in cash and values the company at about $292 million.

The company said its board had considered the offer and found that it “provides Atlantic Lithium shareholders with the most attractive, certain, and accelerated realisation of value on a risk-adjusted basis versus other strategic alternatives”.

Atlantic Lithium’s board is unanimously recommending the deal in the absence of a superior proposal and subject to an independent expert concluding that the scheme is in the best interests of Atlantic Lithium shareholders.

The company said its largest shareholder, Assore International Holdings Limited, which owns 26.4% of the company, had indicated it would vote in favour of the scheme.

Atlantic Lithium Chief Executive Officer Keith Muller said regarding the deal:

The Atlantic Lithium Board has undertaken a detailed evaluation of its strategic options in relation to maximising shareholder value assessed on a risk-adjusted basis and concluded that the Huayou proposal offers an attractive proposition for Atlantic Lithium shareholders, particularly when considered amid ongoing lithium price volatility, complex jurisdictional challenges and against the timing and execution risks attached to financing, developing and operating the Ewoyaa Lithium Project under the Project’s current joint venture arrangements. Huayou’s proposal acknowledges Ewoyaa as a highly attractive hard rock lithium asset capable of serving the growing global electric vehicle and energy storage markets. We welcome the endorsement of the Company’s major shareholder, Assore, towards the Transaction, which is intended to facilitate a clearer direction for the Project towards the achievement of first production of lithium. In doing so, the Transaction is expected to accelerate the delivery of the substantial benefits anticipated for Ghana through the construction and operation of the Project, including, notably, the socio-economic development of the Project’s host communities.

The Ewoyaa project, once developed, would be Ghana’s first lithium mine.

Second approach

Atlantic Lithium said in its most recent quarterly report that it had ceased discussions with “an undisclosed entity in respect of a potential corporate transaction, following the receipt of a conditional, non-binding, indicative change of control proposal for the acquisition of 100% of the Company’s share capital by way of a scheme of arrangement”.

The post Why is this ASX lithium share surging higher today? appeared first on The Motley Fool Australia.

More reading

• ASX lithium stocks to buy amid commodity price rocketing 58% already this year
• Why this ASX 200 rocket stock is crashing again today
• Morgans says these ASX dividend shares are buys
• This ASX gold explorer could more than double on the back of three recent discoveries: broker
• Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar

If you are in the market for some new portfolio additions, then it could pay to listen to what Morgans is saying about the three ASX shares in this article.

Does it rate them as buys, holds, or sells? Here’s what you need to know:

Imdex Ltd (ASX: IMD)

Morgans was pleased with this mining technology company’s performance during the third quarter.

In response, the broker has retained its buy rating on Imdex shares with an improved price target of $5.00. It said:

The 3Q update was strong with constant FX organic revenue growth of +26% YoY. While we pare back our FY26 revenue forecast slightly on FX, we make negligible changes to our EBITDA forecast ($164m +3% vs VA consensus $160m) as mix benefits offset the lower revenue. For FY27-28, we increase our earnings forecasts on confirmation of strong volume growth and recent capital markets activity. While we see capacity for a slight beat in August, in our view, outer year upgrades will be the key driver of the share price from here.

JB Hi-Fi Ltd (ASX: JBH)

This retail giant delivered a “resilient” trading update according to Morgans.

However, it highlights that management appears somewhat cautious ahead of the important end of financial year (EOFY) period.

In response, the broker has retained its accumulate rating with a trimmed price target of $82.90. It said:

JBH provided a solid 3Q26 sales trading update, showing the ongoing resilience in demand for its product categories. Management did caution going into one of the key trading periods (EOFY), that they were seeing supplier component costs increases, stock availability shortages and ongoing heightened competitive activity. We see this as likely reflecting potential margin pressure in the 4Q. We have made minor revisions to earnings (<1%), and our valuation lowers to $82.90 (from $83.50). We maintain our ACCUMULATE recommendation.

Lottery Corporation Ltd (ASX: TLC)

Morgans was pleased to see this lotteries company secure a mammoth 40-year extension to its Victorian Public Lottery Licence.

It believes the deal is strategically positive but acknowledges that the debt taken on to pay for it will weigh on its earnings.

Nevertheless, the broker has upgraded Lottery Corp’s shares to an accumulate rating with an improved price target of $6.00. It said:

The Lottery Corporation (TLC) has secured a 40-year extension of its Victorian Public Lottery Licence to 30 June 2068, paying a $1.145bn upfront premium funded entirely by debt. The duration and timing of the renewal was a mild surprise given the licence was historically offered on 10-year terms and wasn’t expiring until June 2028.

We view the deal as strategically positive, but near-term earnings absorb the cost. Higher D&A and interest from the new debt drag our FY26/27/28F EPS estimates down 3%/13%/15% respectively, partially offset by a beta reduction reflecting materially lower licence renewal risk.

The post What is Morgans saying about Imdex, JB Hi-Fi, and Lottery Corp shares? appeared first on The Motley Fool Australia.

More reading

• Can this red hot ASX materials stock keep charging higher?
• Down 40%: Are JB Hi-Fi shares a bargain buy?
• 2 top ASX dividend stocks on sale, are they buys today?
• The Aussie dollar just hit a 4-year high. Which ASX shares will benefit?
• Warning! Experts name 3 ASX 200 shares to sell

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended The Lottery Corporation. The Motley Fool Australia has recommended The Lottery Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX 200 materials sector rose by 32% last year, largely due to surging share prices for mining companies.

This year, ASX mining shares have fluctuated due to a metals sell-off in late January and the global oil shock now underway.

But overall, the miners are still on an upward trajectory, with the materials sector up 14.15% so far this year.

This compares to a 1.7% lift for the benchmark S&P/ASX 200 Index (ASX: XJO).

While the oil shock created by the war in Iran is impacting miners, the bigger picture is that Australia is at the start of a new long-term mining boom.

A multi-decade green energy transition is underway, and this was the primary driver behind last year’s surge for ASX mining shares.

If you’re looking for investment opportunities, here are two ASX mining shares with buy ratings from the experts today.

Nickel Industries Ltd (ASX: NIC)

The Nickel Industries share price is $1.10, up 4.8% on Thursday, and up 75% over the past 12 months.

Bell Potter has a buy rating on this ASX nickel mining share with a 12-month price target of $1.45.

The broker was impressed with the miner’s 3Q FY26 report, commenting:

Combined with the re-start at Hengjaya, NIC delivered its best quarter of earnings since December 2023.

The broker elaborated:

Our key takeaway is the nickel price leverage demonstrated with this result. RKEF operations stood out, where EBITDA was up 145% from US$35m to US$86m, driven almost entirely by NPI pricing (up 19%) rather than volume (down 4%).

HNI and RNI, which were loss-making in December, both turned profitable in March.

HPAL margins lifted, with EBITDA per tonne up 20% on a 15% increase in price and after a 22% QoQ cost increase.

Catalyst Metals Ltd (ASX: CYL)

The Catalyst Metals share price is $5.36, up 4.1% today, and down 15% over the past 12 months.

Morgans has a buy rating on this ASX gold mining share with a 12-month target of $15.13.

After reviewing the miner’s 3Q FY26 report, Bell Potter said:

We maintain our BUY rating, with valuation supported by strong cash generation and a clear production growth pipeline, albeit with near-term cost pressures emerging.

Catalyst reported gold production of 26.1koz at an all-in sustaining cost (AISC) of A$2,901 per ounce.

Morgans said the miner generated solid operating cash flow of A$103 million at an average realised price of A$7,014 per ounce.

CYL continues to strengthen their balance sheet, adding A$39m during the quarter to close with A$277m in cash and bullion while reinvesting heavily across growth and exploration initiatives.

Growth momentum continues across the Plutonic Belt, with multiple new ore sources advancing (Trident, K2, Old Highway) alongside a high-grade discovery at Cinnamon, supports the pathway to c.200kozpa production.

The post 2 ASX mining shares to buy: experts appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• This ASX materials stock could be set to boom 40% or more
• Top brokers name 3 ASX shares to buy next week
• Brokers name 3 ASX shares to buy right now
• Another broker just recommended this ASX materials stock

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Morgans have run the ruler over two very different companies in the past few days and come out with a buy recommendation for each.

Let’s have a look at what stocks they like at the moment.

Polynovo Ltd (ASX: PNV)

This healthcare company sells its flagship product, NovoSorb, a biodegradable wound dressing that serves as a scaffold for wound regeneration.

In the first half of FY26, the company achieved revenue of $68.2 million from NovoSorb sales, up 26% on the same period the previous year, with strong sales momentum in offshore markets.

The company also has multiple products in its research and development pipeline, and is progressing its key product through regulatory pathways for wider use.

The Morgans team said it had reviewed its FY26 and FY27 forecasts for Polynovo, “and concluded the company is set to deliver a strong 2H26 and continue that growth trajectory into FY27”.

They note that the company will need a strong second half to meet its forecast revenue of $148 million, but they said, “We are confident PNV can deliver on our FY26 forecasts, noting we sit slightly below consensus”.

The Morgans team noted that Polynovo was among the most shorted stocks on the ASX, but they believe this could change.

As they said:

We believe that if PNV can achieve FY26 consensus and if FY27 consensus remains stable which currently has revenue growth of 22% and EBITDA more than doubling, the short position could be reduced materially. It is certainly one stock to watch coming into the August results.

Morgans has a price target of $1.56 on Polynovo shares, compared with the current share price of $1.04.

Digico Infrastructure REIT (ASX: DGT)

This cloud infrastructure provider recently sold a major asset in Chicago for US$750 million, which was a 5% premium to the purchase price.

This has allowed the company to reduce net debt from $1.5 billion to about $500 million and reduce its gearing from 36% to 17%.

The company said while announcing the sale this week:

Together, these initiatives materially strengthen the balance sheet, enhance securityholder returns, and provide financial flexibility to explore capital management initiatives, including returning any excess capital through enhanced distributions.

The company said it was also looking at monetising its LAX1 and LAX2 sites.

Morgans said the Chicago deal was positive as it derisked the company.

Morgans maintained its buy rating on the stock but increased its price target markedly, from $2.70 to $3.60.

The post Morgans names two ASX shares to buy right now for returns of 20% to 50% appeared first on The Motley Fool Australia.

More reading

• Bell Potter says this ASX data centre stock has 15% upside and a 4% yield
• Why DigiCo, HMC Capital, Infratil, and Qantas shares are taking off today
• Why this ASX data centre stock is rocketing over 20% today
• DigiCo Infrastructure REIT slashes debt after Chicago asset sale
• These are the 10 most shorted ASX shares

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has recommended PolyNovo. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Cleanaway Waste Management Ltd (ASX: CWY) share price is in focus after the company reported a key Victorian Supreme Court decision relating to alleged underpayments of landfill levies at its Melbourne Regional Landfill, with a potential financial impact of $6.9 million for FY18.

What did Cleanaway Waste Management report?

• The Supreme Court has ruled in favour of the Environment Protection Authority (EPA) over a $6.9 million landfill levy underpayment claim for FY18.
• Additional EPA audits have highlighted further alleged underpayments of $4.7 million for FY19 and $7.2 million for FY22.
• These additional years are not yet subject to court proceedings and figures exclude costs and interest.
• Cleanaway has 42 days to consider an appeal against the Supreme Court’s decision.

What else do investors need to know?

The court case centres on landfill levies at the Melbourne Regional Landfill, linked to materials sourced by Cleanaway from the adjacent Boral quarry. The EPA argued these materials qualified as ‘waste’ and should attract a government landfill levy, while Cleanaway contended otherwise.

Further details on these proceedings, including potential financial implications, can be found in Note 33 of Cleanaway’s FY25 Financial Report. Cleanaway will review its options, which may include appealing against the ruling.

What’s next for Cleanaway Waste Management?

Cleanaway has 42 days to determine whether to appeal the Supreme Court’s decision. In the meantime, the company aims to continue engaging with stakeholders and maintain full compliance with environmental and regulatory obligations.

The financial impact of the decision, together with the possibility of further audits and proceedings, may affect future results and operational planning. Shareholders will be updated as developments arise.

Cleanaway Waste Management share price snapshot

Over the past 12 months, Cleanaway Waste Management shares have declined 17%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Cleanaway Waste Management hit with landfill levy ruling appeared first on The Motley Fool Australia.

More reading

• Superloop lifts revenue and customer base
• BWP Group announces successful entitlement offer
• Tabcorp faces AUSTRAC compliance probe
• Orica posts record first-half earnings and higher dividend
• NEXTDC wraps up $1.7bn hybrid offer, lifts liquidity

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.